Skip to main content
Clinical Trials/TCTR20180228005
TCTR20180228005
Not yet recruiting
Phase 1

The Comparison of anti-inflammatory versus supplement dose of selenium in mild Graves' orbitopathy

Ratchadapiseksompotch Research fund0 sites87 target enrollmentFebruary 28, 2018

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Clinical activity scoreGraves&#39
Sponsor
Ratchadapiseksompotch Research fund
Enrollment
87
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 28, 2018
End Date
March 1, 2019
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ratchadapiseksompotch Research fund

Eligibility Criteria

Inclusion Criteria

  • \-Mild thyroid eye disease group according to EUGOGO recommendation
  • \-Age above 18 years old
  • \-Normal thyroid hormone level (FT4, FT3\) for at least 6 months
  • \-Thyroid eye symptoms less than 24 months

Exclusion Criteria

  • \-Allergic reaction to selenium
  • \-History of selenium use
  • \-Pregnant or breast\-feeding
  • \-Recent history of orbital and eyelid surgery of less than 6 months

Outcomes

Primary Outcomes

Not specified

Similar Trials